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s It Time to Jettison Complex
echanical Thrombectomy in
avor of Simple Manual
spiration Devices?*
dnan Kastrati, MD,† Robert A. Byrne, MB, BCH,†
lbert Schömig, MD†‡
unich, Germany
hrombus extraction at the time of percutaneous interven-
ion in patients with acute myocardial infarction is an
ntuitively attractive therapy. From a pathophysiological
tandpoint, reduction of thrombus burden before coronary
tent implantation can reduce distal microcirculatory embo-
ization, lower the incidence of subsequent no-reflow phe-
omena, and improve myocardial reperfusion and salvage
1). Recent data from randomized clinical trials supporting
he use of thrombus extraction in primary percutaneous
ntervention (2–4) have led to increased uptake of this
echnology in routine clinical practice and prompted the
ndorsement of thrombus extraction devices (Level of Evi-
ence: B) in a focused update of guidelines on management of
atients with ST-segment elevation myocardial infarction (5).
See page 1298
The apparent benefit associated with thrombus extraction
n primary intervention requires qualification by the obser-
ation that benefit is unlikely to be a class effect. In
articular, clinicians have 2 principal categories of thrombus
xtraction approaches at their disposal: 1) mechanical
hrombectomy devices (e.g., AngioJet, Rescue, Xsizer); and
) manual or aspiration thrombectomy devices (e.g., Diver,
xport, Pronto). Indeed, in the case of 2 recent large-scale
eta-analyses demonstrating a mortality benefit for patients
andomized to thrombus extraction as opposed to those
anaged with conventional primary intervention, this effect
ppeared to be confined to patients treated with manual
hrombectomy devices (6,7). This evidence of differential
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Deutsches Herzzentrum, Technische Universität, Munich, Germany;r
nd the ‡1. Medizinische Klinik, Technische Universität, Munich, Germany. The
uthors have reported that they have no relationships to disclose.fficacy is reflected in the guidelines, which restrict their
ndorsement of thrombus extraction to manual aspiration
evices only (5).
The AngioJet thrombectomy system (Medrad Interven-
ional/Possis, Minneapolis, Minnesota) consists of a hollow
atheter with a high-pressure hypotube through which
aline is pumped to the catheter tip, exiting in a series of
igh-speed jets that are directed retrograde over a mouth
ust proximal to the catheter tip. The action of the jets
reates a localized vacuum on the basis of the Bernouilli/
enturi effect, drawing thrombus into the hollow catheter
nterior, where it is mechanically disrupted and evacuated
rom the body. The device was approved by the Food and
rug Administration in June 1998 on the basis of encour-
ging results among patients with acute coronary syndromes
nrolled in the VeGAS (Vein Graft AngioJet Studies)-1
nd -2 trials (8). However, in the subsequent AIMI (Angio-
et Rheolytic Thrombectomy in Patients Undergoing Pri-
ary Angioplasty for Acute Myocardial Infarction) trial,
andomization to thrombectomy in comparison with con-
entional primary intervention was associated with an in-
rease in infarct size, a reduction in Thrombolysis In
yocardial Infarction (TIMI) flow grade 3 and a higher
ncidence of 30-day adverse clinical outcomes (9).
In this issue of the Journal, Migliorini et al. (10) present
he results of a randomized comparison between mechanical
hrombectomy with the AngioJet rheolytic thrombectomy
atheter and conventional therapy in 501 patients undergo-
ng primary direct stenting for myocardial infarction with
T-segment elevation. The JETSTENT (AngioJet Rheo-
ytic Thrombectomy Before Direct Infarct Artery Stenting
n Patients Undergoing Primary PCI for Acute Myocardial
nfarction) investigators have considerable experience in the
eld of thrombus extraction therapy and are highly qualified
or exploring the role of this therapy in the setting of a
ulticenter randomized controlled trial. The main finding
f this trial is that the authors were unable to discard their
ull hypothesis (i.e., that there was no difference between
he 2 treatment strategies) with respect to the coprimary end
oints of ST-segment elevation resolution and scintigraphic
nfarct size. More specifically, a trend toward more frequent
T-segment resolution with rheolytic thrombectomy
85.8% vs. 78.8%, p  0.043) was not significant in view of
he penalty incurred for multiple primary comparisons. In
ddition, there was no signal of a difference between the 2
trategies with regard to scintigraphically determined infarct
ize (11.8% vs. 12.75%, p 0.40). Regarding the additional
urrogate end points, if anything, a trend was seen in the
ther direction, with numerically lower incidence of both
oronary flow grade 3 and myocardial blush grade 3 as
ssessed by TIMI criteria in the rheolytic thrombectomy
roup.
In terms of clinical outcomes, significant differences were
bserved in favor of the mechanical thrombectomy arm
egarding the composite of major adverse events at 6 and 12
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Mechanical Thrombectomy or Manual Aspiration October 12, 2010:1307–9onths. On 1 level, these results are difficult to reconcile
ith the lack of clear benefit in surrogate markers of
icrocirculatory function. Furthermore, the interpretation
f secondary end points in trials with a negative primary end
oint always entails considerable hazard. Against this, it
ight be observed that these differences are due in large part
o differences in clinical restenosis—a microcirculatory-
ndependent benefit of thrombectomy consequent on more
ccurate lesion assessment, as evidenced by significantly
ower number of stents and total stented length in the
hrombectomy arm. Notably, the JETSTENT study was an
xclusively bare-metal stent study, and the increasing evi-
ence in support of drug-eluting stents in acute myocardial
nfarction might be expected to dilute the benefit of this
ffect (11).
The major features and findings of the 2 largest trials on
he value of the AngioJet thrombectomy system—the
resent JETSTENT trial (10) and the older AIMI trial
9)—are summarized in Table 1. A key difference between
he trials is that the investigators of the JETSTENT trial
nrolled only patients with angiographic evidence of throm-
us, which certainly increases the chances of success of
hrombectomy devices. In terms of results, these 2 trials are
n line in showing no reduction in infarct size and more
nfavorable indicators of epicardial and myocardial flow
ith rheolytic thrombectomy. However, whereas both ST-
egment resolution and clinical end points in the AIMI trial
ere consistent and followed the direction seen in the flow
arameters, the JETSTENT trial showed enhanced ST-
egment resolution and improved clinical outcomes with
heolytic thrombectomy. One possible explanation is that
lthough the prognostic value of surrogate end points has
een validated by large studies, their accuracy is also
ensitive to the assessment method. Furthermore, both of
hese trials were largely underpowered for the analysis of
linical end points, leading to broad and overlapping con-
dence intervals. The investigators of the JETSTENT trial
re absolutely right to advocate the need for larger clinical
rials using the AngioJet device, but considering the slow
nrollment rate in their multicenter trial, the chances of
ajor Features and Findings of 2 Largest Trials on Value of AngiojeTable 1 Major Features and Findings of 2 Largest Trials on Val
JE
Rheolytic
Angiographic evidence of thrombus as an inclusion criterion
ST-segment elevation resolution* 8
Post-procedural TIMI flow grade 3 8
Post-procedural TIMI blush grade 3 7
Scintigraphic infarct size† 1
30-day incidence of MACE
The ST-segment elevation resolution was defined as a reduction in ST-segment elevation of 5
ETSTENT trial and as mean value in the AIMI trial.
AIMI Angiojet Rheolytic Thrombectomy in Patients Undergoing Primary Angioplasty for Acute M
n Patients Undergoing Primary PCI for Acute Myocardial Infarction; MACE  major adverse cardiouch a trial coming to pass seem very low. (In light of the often superior thrombus extraction effi-
iency with mechanical thrombectomy, what explains the
isappointing outcomes with mechanical devices in general
nd the JETSTENT trial in particular? At least 2 possible
xplanations should be considered. First, mechanical
hrombectomy devices are considerably more complex to
perate than manual aspiration catheters. They tend to be
ulkier, have longer learning curves, require considerably
engthened procedure times, and their use is more often
estricted by coronary anatomy. The relevance of these
ssues is amplified in the setting of acute myocardial infarc-
ion, which is often performed out-of-hours, with reduced
taffing capabilities and higher rates of procedural compli-
ations. Second, the rheolytic thrombectomy catheter has
ome specific limitations, which include: 1) a propensity to
mpair rather than enhance distal microcirculatory perfusion
as discussed in the preceding text); and 2) a recommenda-
ion for prophylactic temporary pacemaker implantation
ue to a high incidence of symptomatic bradycardia (likely
ue to hemolysis-induced distal adenosine release, especially
elevant when the infarct-related artery is a dominant right
oronary or circumflex artery). A notable feature of the
urrent study is that the investigators addressed these latter
evice-specific concerns by dispensing with the traditional
pproach of first crossing the culprit lesion and then
ngaging the device with a retrograde pullback. Their
mployment of a single anterograde pass technique may
nderlie the very low rate of temporary pacemaker deploy-
ent in the current study.
The results with manual thrombectomy devices are far
ore encouraging than those with mechanical thrombus
xtraction (2–4,6,7). In general, the devices are considerably
ore user-friendly, and consequently have shorter learning
urves. Nevertheless, a number of issues relating to the more
recise role of thrombus extraction in primary intervention
or myocardial infarction remain open. For example, should
strategy of universal device usage in the culprit lesion of
ll patients with ST-segment elevation—as undertaken in
APAS (Thrombus Aspiration During Percutaneous Cor-
nary Intervention in Acute Myocardial Infarction Study)
ombectomy SystemAngiojet Thrombectomy System
T Trial (n  501) AIMI Trial (n  480)
bectomy Control Rheolytic Thrombectomy Control
Yes No No
78.8% 60% 68%
85.9% 91.8% 97.0%
79.1% 30.6% 36.8%
12.75% 12.5% 9.8%
6.9% 6.7% 1.7%
he JETSTENT trial and 70% in the AIMI trial. †Infarct size was shown as a median value in the
ial Infarction; JETSTENT AngioJet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting
ar events; TIMI  Thrombolysis In Myocardial Infarction.t Thrue of
TSTEN
Throm
Yes
5.8%
0.6%
2.1%
1.8%
3.1%
0% in t4)—be preferred to an intuitively more reasonable selective
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October 12, 2010:1307–9 Mechanical Thrombectomy or Manual Aspirationatient approach? And if a selective strategy is employed,
hich patients are likely to benefit most? Patients with
isible and large thrombus burden of the culprit vessel are
bviously the optimal candidates, especially if they present
ith shorter ischemic times.
onclusions
he JETSTENT investigators are to be commended for a
ell-designed and executed study in an effort to further help
atients with acute myocardial infarction undergoing per-
utaneous coronary intervention. However, the authors’
nthusiastic interpretation of the results may be driven more
y their attraction to the concept of thrombectomy than by
he strength of the evidence shown in the study. Device
omplexity may be a significant limitation of rheolytic
hrombectomy, especially in out-of-hours and emergency
ituations, and what evidence is available is far from being a
otivation for its adoption into routine practice. In keeping
ith the findings of recent meta-analyses and in line with
urrent guideline recommendations, the message emerging
s clear: thrombus extraction seems to be a useful adjunctive
herapy for patients undergoing primary percutaneous cor-
nary intervention for ST-segment elevation myocardial
nfarction, and the modality of choice appears to be simple
anual aspiration.
eprint requests and correspondence: Dr. Adnan Kastrati,
eutsches Herzzentrum, Lazarettstrasse 36, Munich 80636, Ger-
any. E-mail: kastrati@dhm.mhn.de.
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